Quantitative MODS-Wayne Assay for Rapid Detection of Pyrazinamide Resistance in from Sputum Samples

Overview

Journal Microbiol Spectr

Specialty Microbiology

Date 2024 Nov 14

PMID 39540764

Authors

Emily Toscano-Guerra

Roberto Alcantara

Katherine Lozano Untiveros

Robert Gilman

Louis Grandjean

Mirko Zimic

Patricia Sheen

Affiliations

Soon will be listed here.

Abstract

Importance: PZA susceptibility testing continues to be a challenge, particularly in countries with high TB incidence. In response to this pressing need, we have developed a quantitative MODS-Wayne (MODS-WQ) assay. This approach offers a direct and cost-effective solution representing a significant advancement in TB diagnostics, particularly benefiting resource-limited laboratories, primarily in developing regions. The MODS-WQ assay stands out for its ability to quantify pyrazinoic acid (POA) production, as a reliable indicator of PZA resistance. Unlike traditional qualitative assays, MODS-WQ eliminates the inherent subjectivity in interpretation, providing more accurate and actionable results. Moreover, the MODS-WQ approach accounts for critical factors influencing PZA resistance, including enzymatic efficiency and efflux pump activity. By integrating these factors into the detection process, our methodology offers a comprehensive understanding of PZA resistance levels, enabling tailored treatment strategies for patients.

References

Shah M, Chihota V, Coetzee G, Churchyard G, Dorman S . Comparison of laboratory costs of rapid molecular tests and conventional diagnostics for detection of tuberculosis and drug-resistant tuberculosis in South Africa. BMC Infect Dis. 2013; 13:352. PMC: 3733609. DOI: 10.1186/1471-2334-13-352. View

Xu X, Zhang L, Shen D, Wu H, Liu Q . Oxygen-dependent oxidation of Fe(II) to Fe(III) and interaction of Fe(III) with bovine serum albumin, leading to a hysteretic effect on the fluorescence of bovine serum albumin. J Fluoresc. 2007; 18(1):193-201. DOI: 10.1007/s10895-007-0263-4. View

Sodja E, Koren S, Toplak N, Truden S, Zolnir-Dovc M . Next-generation sequencing to characterise pyrazinamide resistance in Mycobacterium tuberculosis isolates from two Balkan countries. J Glob Antimicrob Resist. 2021; 29:507-512. DOI: 10.1016/j.jgar.2021.09.019. View

Zimic M, Fuentes P, Gilman R, Gutierrez A, Kirwan D, Sheen P . Pyrazinoic acid efflux rate in Mycobacterium tuberculosis is a better proxy of pyrazinamide resistance. Tuberculosis (Edinb). 2011; 92(1):84-91. PMC: 3269536. DOI: 10.1016/j.tube.2011.09.002. View

Zhang Y, Permar S, Sun Z . Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol. 2002; 51(1):42-49. DOI: 10.1099/0022-1317-51-1-42. View

Pang Y, Zhu D, Zheng H, Shen J, Hu Y, Liu J . Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis. 2017; 17(1):711. PMC: 5674869. DOI: 10.1186/s12879-017-2761-6. View

Ramirez-Busby S, Rodwell T, Fink L, Catanzaro D, Jackson R, Pettigrove M . A Multinational Analysis of Mutations and Heterogeneity in PZase, RpsA, and PanD Associated with Pyrazinamide Resistance in M/XDR Mycobacterium tuberculosis. Sci Rep. 2017; 7(1):3790. PMC: 5476565. DOI: 10.1038/s41598-017-03452-y. View

Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P . Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012; 56(10):5186-93. PMC: 3457413. DOI: 10.1128/AAC.05385-11. View

Moore D, Evans C, Gilman R, Caviedes L, Coronel J, Vivar A . Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med. 2006; 355(15):1539-50. PMC: 1780278. DOI: 10.1056/NEJMoa055524. View

10.

Ueno H, Urazono H, Kobayashi T . Serum albumin forms a lactoferrin-like soluble iron-binding complex in presence of hydrogen carbonate ions. Food Chem. 2013; 145:90-4. DOI: 10.1016/j.foodchem.2013.07.143. View

11.

Owusu E, Newman M . Microscopic Observation Drug Susceptibility (MODS) Assay: A Convenient Method for Determining Antibiogram of Clinical Isolates of in Ghana. Med Sci (Basel). 2020; 8(1). PMC: 7151611. DOI: 10.3390/medsci8010005. View

12.

Calderon R, Velasquez G, Becerra M, Zhang Z, Contreras C, Yataco R . Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru. Int J Tuberc Lung Dis. 2017; 21(8):894-901. PMC: 5555119. DOI: 10.5588/ijtld.16.0850. View

13.

Mok S, Roycroft E, Flanagan P, Montgomery L, Borroni E, Rogers T . Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother. 2021; 65(8):e0261720. PMC: 8284449. DOI: 10.1128/AAC.02617-20. View

14.

Modlin S, Marbach T, Werngren J, Mansjo M, Hoffner S, Valafar F . Atypical Genetic Basis of Pyrazinamide Resistance in Monoresistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2021; 65(6). PMC: 8315952. DOI: 10.1128/AAC.01916-20. View

15.

Catanzaro D, Trollip A, Seifert M, Georghiou S, Garfein R, Rodwell T . Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for . Eur Respir J. 2017; 49(4). PMC: 6141189. DOI: 10.1183/13993003.02215-2016. View

16.

Sheen P, Requena D, Gushiken E, Gilman R, Antiparra R, Lucero B . A multiple genome analysis of Mycobacterium tuberculosis reveals specific novel genes and mutations associated with pyrazinamide resistance. BMC Genomics. 2017; 18(1):769. PMC: 5637355. DOI: 10.1186/s12864-017-4146-z. View

17.

Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F . Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Clin Microbiol. 2009; 48(1):300-1. PMC: 2812260. DOI: 10.1128/JCM.01775-09. View

18.

Sheen P, Lozano K, Gilman R, Valencia H, Loli S, Fuentes P . pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb). 2013; 93(5):515-22. PMC: 3755357. DOI: 10.1016/j.tube.2013.03.005. View

19.

Meinzen C, Proano A, Gilman R, Caviedes L, Coronel J, Zimic M . A quantitative adaptation of the Wayne test for pyrazinamide resistance. Tuberculosis (Edinb). 2016; 99:41-46. DOI: 10.1016/j.tube.2016.03.011. View

20.

Ei P, Mon A, Htwe M, Win S, Aye K, San L . Pyrazinamide resistance and pncA mutations in drug resistant Mycobacterium tuberculosis clinical isolates from Myanmar. Tuberculosis (Edinb). 2020; 125:102013. DOI: 10.1016/j.tube.2020.102013. View